# MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

> **NCT01498952** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 6 (actual)

## Conditions studied

- Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** MEDI-573 (1 of 3 doses)
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01498952
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-17
- **Primary completion:** 2013-04-09
- **Final completion:** 2013-04-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01498952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01498952, "MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01498952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*